Joshua J. Gruber

Contemporary therapy for small node-negative triple-negative breast cancer: a retrospective cohort study

Introduction Multi-agent neoadjuvant therapy (NAT) with immune checkpoint blockade is standard treatment for Stage II–III triple-negative breast cancer (TNBC), though its role in smaller node-negative tumors remains unclear. Methods We performed a retrospective multi-institutiona...